Nat Commun April 2023 PMID 37037829

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.

Xiaomeng Hu, Karl Manner, Rowena DeJesus, Kathy White, Corie Gattis, Priscilla Ngo, Christopher Bandoro, Eleonore Tham, Elaine Y Chu, Chi Young, Frank Wells, Ronald Basco, Annabelle Friera, Divy Kangeyan, Pascal Beauchesne

Full text PDF Download social card

Mentions

Peak: 5 in Apr 2023

across 5 sources since Apr 2023

Extended reach

39,555

potential audience

Total likes

Video views

Mentions per month

Apr 2023 – Jan 2025

Where it's discussed

X / Twitter8 posts
News4 articles
Blogs3 articles
Facebook2 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions mainly support the significance of hypoimmune CAR T-cell research, highlighting aspects like the use of CRISPR technology and immune evasion strategies, with phrases like 'one step closer' and 'lasting tumor control'. The tone mixes curiosity with optimism, especially around the innovation of universal therapeutics, although technical details like CD47 knockins indicate a relatively engaged audience familiar with the science.

AgreementModerate agreement

Most discussions express support or curiosity about the research, indicating a general agreement with its significance.

InterestHigh interest

Posts show high interest, especially with references to the innovative methods like CRISPR and the potential for universal therapies.

EngagementModerate engagement

Some comments delve into technical details like B2M, CIITA, TRAC knockouts, and safety strategies, demonstrating moderate engagement.

ImpactModerate impact

The research seems to be viewed as potentially game-changing, but the discussion remains focused on future implications rather than immediate application.

Abstract in brief

Hypoimmune antiCD19 CAR T cells are engineered using CRISPR/Cas9 to disrupt immune-recognition genes, making them able to evade the immune system and produce long-lasting tumor control.
These modified T cells, compared to standard allogeneic CAR T cells, demonstrate similar cancer-killing ability in vitro but significantly outperform in fully immunocompetent humanized mice by persisting longer and providing durable tumor clearance.
Safety strategies, like CD47 targeting, can specifically eliminate these hypoimmune CAR T cells if needed, potentially overcoming previous challenges of immune rejection and limited persistence associated with allogeneic CAR T therapies.]

Read the full abstract

All mentions

Hypoimmune Anti-CD19 CAR T Cells Enable Long-Term Tumor Control in Mice

Hypoimmune antiCD19 CAR T cells are engineered with CRISPR/Cas9 to evade immune detection, enabling durable tumor clearance. These modified T cells outperform standard allogeneic CARs in humanized mice, offering…

STEM RTCL TV · Jul 28, 2023 72 views

Charles Gordon

@princetongb · X

https://t.co/RtJToy42HZ $SANA https://t.co/Y4vcFJgCGj

Jan 8, 2025 · 5 likes · 4,784 followers View post →

flintflant

@flintflan · X

RT @JacobPlieth: I'm still curious about $SANA 's approach to using CD47 https://t.co/Qt2cq02Opo

Feb 7, 2024 · 1 share · 266 followers View post →

Jacob Plieth

@JacobPlieth · X

I'm still curious about $SANA 's approach to using CD47 https://t.co/Qt2cq02Opo

Feb 7, 2024 · 10 likes · 1 share · 30,632 followers View post →

Gayathri Vijayakumar

@Gayathri_Vijayk · X

Apr 30, 2023 · 10 likes · 444 followers View post →

CRISP_SCIENCE

@ScienceCrisp · X

Apr 19, 2023 · 1,917 followers View post →

ImmunotherapyPapers

@Immunotx_papers · X

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice https://t.co/xXtnlKBlok

Apr 17, 2023 · 247 followers View post →

Creative-Biolabs

@creativebiolabs · X

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. https://t.co/zfNPTigvYJ

Apr 11, 2023 · 1,117 followers View post →

minnlab_litbot

@MLitbot · X

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice https://t.co/D4ILoC3Y70 https://t.co/AL4EaguO9L

Apr 11, 2023 · 72 followers View post →